212 related articles for article (PubMed ID: 22085632)
21. Biophysical properties of chitosan/siRNA polyplexes: profiling the polymer/siRNA interactions and bioactivity.
Holzerny P; Ajdini B; Heusermann W; Bruno K; Schuleit M; Meinel L; Keller M
J Control Release; 2012 Jan; 157(2):297-304. PubMed ID: 21884740
[TBL] [Abstract][Full Text] [Related]
22. Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase.
Malm-Erjefält M; Bjørnsdottir I; Vanggaard J; Helleberg H; Larsen U; Oosterhuis B; van Lier JJ; Zdravkovic M; Olsen AK
Drug Metab Dispos; 2010 Nov; 38(11):1944-53. PubMed ID: 20709939
[TBL] [Abstract][Full Text] [Related]
23. Dipeptidyl peptidase IV and its inhibitors: therapeutics for type 2 diabetes and what else?
Juillerat-Jeanneret L
J Med Chem; 2014 Mar; 57(6):2197-212. PubMed ID: 24099035
[TBL] [Abstract][Full Text] [Related]
24. (2S,4S)-4-Fluoro-1-{[(2-hydroxy-1,1-dimethylethyl)amino]acetyl}-pyrrolidine-2-carbonitrile monobenzenesulfonate (TS-021) is a selective and reversible dipeptidyl peptidase IV inhibitor.
Tajima A; Yamamoto K; Kozakai A; Okumura-Kitajima L; Mita Y; Kitano K; Jingu S; Nakaike S
Eur J Pharmacol; 2011 Mar; 655(1-3):99-107. PubMed ID: 21262219
[TBL] [Abstract][Full Text] [Related]
25. A Novel Dipeptidyl Peptidase IV Inhibitory Tea Peptide Improves Pancreatic β-Cell Function and Reduces α-Cell Proliferation in Streptozotocin-Induced Diabetic Mice.
Lu Y; Lu P; Wang Y; Fang X; Wu J; Wang X
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30646613
[TBL] [Abstract][Full Text] [Related]
26. Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice.
Moritoh Y; Takeuchi K; Hazama M
J Pharmacol Exp Ther; 2009 May; 329(2):669-76. PubMed ID: 19208898
[TBL] [Abstract][Full Text] [Related]
27. siRNA Delivery with Chitosan: Influence of Chitosan Molecular Weight, Degree of Deacetylation, and Amine to Phosphate Ratio on in Vitro Silencing Efficiency, Hemocompatibility, Biodistribution, and in Vivo Efficacy.
Alameh M; Lavertu M; Tran-Khanh N; Chang CY; Lesage F; Bail M; Darras V; Chevrier A; Buschmann MD
Biomacromolecules; 2018 Jan; 19(1):112-131. PubMed ID: 29211954
[TBL] [Abstract][Full Text] [Related]
28. The influence of polymeric properties on chitosan/siRNA nanoparticle formulation and gene silencing.
Liu X; Howard KA; Dong M; Andersen MØ; Rahbek UL; Johnsen MG; Hansen OC; Besenbacher F; Kjems J
Biomaterials; 2007 Feb; 28(6):1280-8. PubMed ID: 17126901
[TBL] [Abstract][Full Text] [Related]
29. The dipeptidyl peptidase-4 inhibitor linagliptin attenuates inflammation and accelerates epithelialization in wounds of diabetic ob/ob mice.
Schürmann C; Linke A; Engelmann-Pilger K; Steinmetz C; Mark M; Pfeilschifter J; Klein T; Frank S
J Pharmacol Exp Ther; 2012 Jul; 342(1):71-80. PubMed ID: 22493041
[TBL] [Abstract][Full Text] [Related]
30. Chitosan-modified poly(D,L-lactide-co-glycolide) nanospheres for plasmid DNA delivery and HBV gene-silencing.
Zeng P; Xu Y; Zeng C; Ren H; Peng M
Int J Pharm; 2011 Aug; 415(1-2):259-66. PubMed ID: 21645597
[TBL] [Abstract][Full Text] [Related]
31. GLP-1 agonists and dipeptidyl-peptidase IV inhibitors.
Gallwitz B
Handb Exp Pharmacol; 2011; (203):53-74. PubMed ID: 21484567
[TBL] [Abstract][Full Text] [Related]
32. The impact of nanoparticles on the mucosal translocation and transport of GLP-1 across the intestinal epithelium.
Araújo F; Shrestha N; Shahbazi MA; Fonte P; Mäkilä EM; Salonen JJ; Hirvonen JT; Granja PL; Santos HA; Sarmento B
Biomaterials; 2014 Nov; 35(33):9199-207. PubMed ID: 25109441
[TBL] [Abstract][Full Text] [Related]
33. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
Drucker DJ; Nauck MA
Lancet; 2006 Nov; 368(9548):1696-705. PubMed ID: 17098089
[TBL] [Abstract][Full Text] [Related]
34. Low molecular weight chitosan nanoparticulate system at low N:P ratio for nontoxic polynucleotide delivery.
Alameh M; Dejesus D; Jean M; Darras V; Thibault M; Lavertu M; Buschmann MD; Merzouki A
Int J Nanomedicine; 2012; 7():1399-414. PubMed ID: 22457597
[TBL] [Abstract][Full Text] [Related]
35. Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes.
Green BD; Flatt PR; Bailey CJ
Diab Vasc Dis Res; 2006 Dec; 3(3):159-65. PubMed ID: 17160910
[TBL] [Abstract][Full Text] [Related]
36. Fc fusion to glucagon-like peptide-1 inhibits degradation by human DPP-IV, increasing its half-life in serum and inducing a potent activity for human GLP-1 receptor activation.
Kim DM; Chu SH; Kim S; Park YW; Kim SS
BMB Rep; 2009 Apr; 42(4):212-6. PubMed ID: 19403044
[TBL] [Abstract][Full Text] [Related]
37. GLP-1 based therapy for type 2 diabetes.
Arulmozhi DK; Portha B
Eur J Pharm Sci; 2006 May; 28(1-2):96-108. PubMed ID: 16488579
[TBL] [Abstract][Full Text] [Related]
38. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).
Thornberry NA; Gallwitz B
Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):479-86. PubMed ID: 19748065
[TBL] [Abstract][Full Text] [Related]
39. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
Jellinger PS
Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084
[TBL] [Abstract][Full Text] [Related]
40. Investigation into the bioavailability of milk protein-derived peptides with dipeptidyl-peptidase IV inhibitory activity using Caco-2 cell monolayers.
Lacroix IME; Chen XM; Kitts DD; Li-Chan ECY
Food Funct; 2017 Feb; 8(2):701-709. PubMed ID: 28098291
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]